Adobe is hovering around a two-year low. Yet the company is forecasting record sales and earnings. AI has yet to make a large impact on Adobe's bottom line. After tumbling 25.5% in 2024 despite a ...

After soaring following the election, Tesla (NASDAQ: TSLA) stock ran into a wall in February as a number of news items, macro challenges and CEO Elon Musk's involvement in the Department of ...

After soaring following the election, Tesla (NASDAQ: TSLA) stock ran into a wall in February as a number of news items, macro challenges and CEO Elon Musk's involvement in the Department of Government ...

One group of stocks that has been punished during this current market downturn is telecoms. On Tuesday, they got little respite, on news of remarks from a top executive at one of their incumbent ...

The egg shortage and its effect on prices aren't doing the company any favors. It recently imposed surcharges on the many meals it makes with the protein, but these levies aren't universal. For ...

Shares of online learning platform company Nerdy (NYSE: NRDY) fell hard today after the company reported its fourth-quarter results yesterday. While sales and earnings beat Wall Street's consensus ...

Hims and Hers' stock fell over 19% in after-hours trading on Monday after its CEO said the company would no longer sell compounded versions of mega-hit weight loss drugs. "We will have to start ...

Looking for a decent deal on an unlocked Android flagship? The excellent Google Pixel 9 Pro is $799 (was $999) at Amazon today - a match for the best price I've seen yet on the device. Today's ...

Hims & Hers (NYSE:HIMS) stock tumbled 20% in post-market trading Monday after the company released its Q4 earnings report and 2025 guidance amid a possible FDA crackdown on its GLP-1 weight-loss ...

An icon in the shape of a lightning bolt. Impact Link Tesla sales in Europe plunged in January, falling 45% compared with the same month last year, while overall sales of electric vehicles ...

Hims and Hers plans to stop selling compounded weight loss drugs after an FDA update. Hims and Hers' stock fell over 19% in after-hours trading on Monday. The FDA removed semaglutide injections ...